Phase III Randomized Study Of Sorafenib Plus Doxorubicin Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma (HCC)- CALGB 80802 (Alliance) Abou-Alfa, Ghassan K. , Niedzwieski, Donna , Knox, Jennifer J. ... - ASCO GI - J. Clin. Oncol. - 2016 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - - JAMA Oncol - 2019 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80802
Platelet count at baseline (Plt) and outcomes in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S) in CALGB 80802 (Alliance) (C8) Abou-Alfa, Ghassan K. , Shi, Qian , Knox, Jennifer J. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80802
A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study. Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0426
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426 Adjei, A. A. , Mandrekar, S. J. , Dy, G. K. , Molina, J. R. ... - - J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0426
A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer. Adjei, A. A. , Molina, J. R. , Hillman, S. L. , Luyun, R. F. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0326
Correlation between polymorphisms in the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer (NSCLC): An NCCTG N0026 based study. Abstract 198. Adjei, A. , Salavaggione, O. , Mandrekar, S. , Dy, G. ... - NCI TSM - - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - NCCTG-N0026
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Adjei, Araba A , Salavaggione, Oreste E , Mandrekar, Sumithra J ... - - J Thorac Oncol - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - N0026
Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance) Advani, Anjali S. , Sanford, Ben , Luger, Selina , Devidas, Meenakshi ... - ASH - Blood - 2013 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C10403
Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial Advani, Pooja P. , Ballman, Karla V. , Dockter, Travis J. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial. Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831
A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: an Alliance Foundation trial (AFT-19) Aggarwal, Rahul , Eggener, Scott , Chen, Ronald , Heller, Glenn ... - ASCO - J Clin Oncol - 2018 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - AFT-19
The Effect of Prior Androgen Synthesis Inhibition on Outcomes of Subsequent Therapy with Docetaxel in Patients with Metastatic Castrate Resistant Prostate Cancer: Results from a Retrospective Analysis of a Randomized Phase 3 Clinical Trial (CALGB 90401) (Alliance) Aggarwal, Rahul , Halabi, Susan , Kelly, William Kevin ... - - Cancer - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90401
Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM) CALGB 100104 (Alliance) Ailawadhi, Sikander , McCarthy, Philip L. , Holstein, Sarah A. ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Transplant - CALGB-100104 , E4A03 , MM-002 , MM-009
Management of Recurrent Prostate Cancer after Radiotherapy: Long-term results from CALGB 9687, a Contemporary Prospective Multi-institutional Salvage Prostatectomy Series Al-Daghmin, A , Sokoloff, MH , Halabi, S , Sanford, BL , Eastham, JA ... - AUA - J Urology - 2014 Abstract - Primary Endpoint - Long-Term-Followup Analysis - GU - CALGB-9687
Efficacy and toxicity of cetuximab (C225) plus mFOLOFX6 in patients (pts) with nonoptimally resectable, colorectal metastases (MCRC) confined to the liver Alberts, S. R. , Donohue, J. H. , Mahoney, M. R. , Nelson, G. D. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N014A
NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC)--interim review of toxicity Alberts, S. R. , Morlan, B. W. , Kim, G. P. , Pitot, H. C. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2007 Abstract - Primary Endpoint - Preliminary Analysis - GI - NCCTG-N044J
Adjuvant mFOLFOX6 +/- Cetuxiumab in KRAS Wild Type Patients With Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147. Alberts, S. R. , Sargent, D. J. , Smyrk, T. C. , Shields, A. F. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N0147
Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver. Alberts, S. , Mahoney, M. R. , Donohue, J. H. , Roh, M. S. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - NCCTG-N9945
Randomized phase II trial of extended versus standard neoadjuvant therapy for esophageal cancer, NCCTG (Alliance) trial N0849 Alberts, S. , Soori, G. , Shi, Q. , Wigle, D. , Sticca, R. , Miller, R. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Preliminary Analysis - GI - N0849
Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Fitch, Tom R. , Kim, George P. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N044J
Gemcitabine and Doxetaxel for Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial Alberts, Steven R. , Reid, Joel M. , Morlan, Bruce W. , Farr, Gist H. ... - - Am. J. Clin. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0041
Alternating Systemic and Hepatic Artery Infusion Therapy for Resected Liver Metastases From Colorectal Cancer: A North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) Phase II Intergroup Trial, N9945/CI-66 Alberts, Steven R. , Roh, Mark S. , Mahoney, Michelle R. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - N9945
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer Alberts, Steven R. , Sargent, Daniel J. , Nair, Suresh ... - - JAMA - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - N0147
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. Alberts, Steven R , Sande, Jonathan R , Foster, Nathan R ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-N9943
Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-964251
ACOSOG Z0030 Study Group: Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective ACOSOG Z0030 trial Allen, M. S. , Darling, G. E. , Decker, P. A. , Putnam, J. B. Jr ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503) Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - AATS - - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-140503
Perioperative mortality and Morbidity after Lobar versus Sublobar Resection for early stage lung cancer: A post-hoc analysis of an international randomized phase III trial (CALGB/Alliance 140503) Altorki, Nasser K. , Wang, Xiaofei , Wigle, Dennis , Gu, Lin ... - - Lancet Respir Med - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0010
Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods An, Ming-Wen , Han, Yu , Meyers, Jeffrey P. , Bogaerts, Jan ... - - J. Clin. Oncol - 2015 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9741
Exploring the statistical and clinical impact of two interim analyses on the phase II design with option for direct assignment An, Ming-Wen , Mandrekar, Sumithra J. , Edelman, Martin J. ... - - Contemp Clin Trials - 2014 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-30203
Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0776
Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902. Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902
Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS) -- Findings from the ACCENT dataset. Andre, T. , Shi, Q. , Yothers, G. , Bot, B. , Haller, D. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Phase II clinical trial of denileukin diftitox in combination with rituximab in previously untreated follicular B-cell non-Hodgkins lymphoma Ansell, S. M. , Tang, H. , Nowakowski, G. S. , Nikcevich, D. A. ... - ASH - 53rd ASH Annual Meeting and Exposition - 2010 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma Ansell, Stephen M. , Inwards, David J. , Rowland, Kendrith M. ... - - Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N0186
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma Ansell, Stephen M. , Novak, Anne J. , Ziesmer, Steven ... - - Am J Hematol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Lymphoma - NCCTG-98-78-51
Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Lancet Oncol - 2011 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - N038H
Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma Ansell, Stephen M. , Tang, Hui , Kurtin, Paul J. ... - - Leukemia - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - NCCTG-N0682
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). Anurag, Meenakshi , Zhu, Mayanne , Huang, Chen , Vasaikar, Suhas ... - - J. Natl. Cancer Inst. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy Apolo, Andrea B. , Ostrovnaya, Irina , Halabi, Susan ... - - J. Natl. Cancer Inst - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90102
External validation of prognostic models for overall survival (OS) in patients (pts) with advanced cancer (UC) treated with cisplatin-based chemotherapy. Apolo, Andrea Borghese , Philips, George , Ostrovnaya, Irina ... - - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90102
Alliance A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (MIBC) (AMBASSADOR) vs Observation Apolo, Andrea , Rosenberg, Jonathan , Morris, Michael ... - ASCO GU - J Clin Oncol - 2019 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - GU - A031501
Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer. Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0338
Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Armer, Nathan C. ... - - Support Care Cancer - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Ostby, Pamela L. ... - - JAMA Surg - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance) Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Ashley, Amanda C , Sargent, Daniel J , Alberts, Steven R ... - - Cancer - 2007 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - NCCTG-9741
Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance) Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Myeloma - CALGB-100104
Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502 Attar, E. C. , Donohue, K. A. , Amrein, P. C. , Wadleigh, M. ... - - Blood - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - CALGB-10502
A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502. Attar, E. C. , Johnson, J. L. , Amrein, P. C. , Lozanski, G. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10502
Cytarabine, daunorubicin and etoposide (ADE) chemotherapy in acute myeloid leukemia (AML) patients >= 60 years (CALGB 9720) Baer, M. R. , George, S. L. , Sanford, B. L. , Bothun, S. M. ... - - Blood - 2007 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720
Treatment of older patients with de novo acute myeloid leukemia (AML) with one or more postremission chemotherapy courses: Analysis of four CALGB studies Baer, M. R. , George, S. L. , Sanford, B. L. , Stone, R. M. ... - ASCO - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C8525 , CALGB-10201 , CALGB-8923 , CALGB-9720
Cancer and Leukemia Group B studies of recombinant Interleukin-2 maintenance therapy in acute myeloid leukemia Baer, M. R. , Kolitz, J. E. , George, S. L. , Caligiuri, M. A. ... - - Ann Hematol - 2008 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-19808
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 Baer, MR , George, SL , Sanford, BL , Mrózek, K , Kolitz, JE ... - - Leukemia - 2011 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-9720
Low-Dose Interleukin-2 Immunotherapy Does Not Improve Outcome of Patients Age 60 Years and Older With Acute Myeloid Leukemia in First Complete Remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J Clin Oncol - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-8461 , CALGB-9720 , CALGB-9760
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Baer, Maria R. , George, Stephen L. , Caligiuri, Michael A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - CALGB-10201 , CALGB-10502 , CALGB-10503 , CALGB-10603 , CALGB-19808 , CALGB-8525 , CALGB-8923 , CALGB-9022 , CALGB-9222 , CALGB-9420 , CALGB-9621 , CALGB-9720
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance) Baggstrom, Maria Q. , Socinski, Mark A. , Wang, Xiaofei F. , Gu, Lin ... - - J Thorac Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30607 , CALGB-70701
Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Bajorin, Dean F , Halabi, Susan ... - - Clin Genitourin Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-99903
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Ballman, Karla V. , Buckner, Jan C. , Brown, Paul D. ... - - Neuro-oncol - 2007 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D
Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators Bardia, A. , Loprinzi, C. , Grothey, A. , Nelson, G. , Alberts, S. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N0148
Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators Bardia, Aditya , Loprinzi, Charles , Grothey, Axel , Nelson, Garth ... - - Semin Oncol - 2010 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - N0148
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Bartlett, N L , Niedzwiecki, D , Johnson, J L , Friedberg, J W ... - - Ann. Oncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804
A phase I/II study of gemcitabine, vinorelbine, and liposomal doxorubicin for relapsed Hodgkin's disease: Preliminary results of CALGB 59804 Bartlett, N. , Niedzwiecki, D. , Johnson, J. , Friedberg, J. W. ... - - Proc Am Soc Clin Oncol - 2003 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59804
Phase II Study of 9-aminocamptothecin in Previously Treated Lymphomas: Results of Cancer and Leukemia Group B 9551 Bartlett, Nancy L. , Johnson, Jeffrey L. , Wagner-Johnston, Nina ... - - Cancer Chemother. Pharmacol. - 2009 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-9551
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50303
Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Patients with Hematologic Malignancies Who Relapse following Autologous Transplantation: A Multi-Institutional Prospective Study from the Cancer and Leukemia Group B (CALGB trial 100002) Bashey, Asad , Owzar, Kouros , Johnson, Jeffrey L. ... - - Biol. Blood Marrow Transplant. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100002
Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy Beltran, Himisha , Wyatt, Alexander W , Chedgy, Edmund C ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GU - CALGB-90203
Randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). Bergsland, Emily K. , Mahoney, Michelle R. , Asmis, Timothy R. ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - GI - A021202
Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials Bernhard, Jürg , Luo, Weixiu , Ribi, Karin , Colleoni, Marco ... - - Lancet Oncol. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007 Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163
High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials Berry, Donald A. , Ueno, Naoto T. , Johnson, Marcella M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - INT-0163
Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 Bertagnolli, M. M. , Niedzwiecki, D. , Hall, M. , Jewell, S. D. ... - ASCO - J. Clin. Oncol. - 2009 Abstract - Secondary Endpoint - Primary Analysis - GI - C9581
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 Bertagnolli, Monica M. , Niedzwiecki, Donna , Compton, Carolyn C. ... - - J Clin Oncol - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803 Bertagnolli, Monica M. , Redston, Mark , Compton, Carolyn C. ... - - J Clin Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - C89803 , C9581 , C150705
p27Kip1 in Stage III Colon Cancer: Implications for Outcome Following Adjuvant Chemotherapy in CALGB 89803 Bertagnolli, Monica M. , Warren, Robert S. , Niedzwiecki, Donna ... - - Clin Cancer Res - 2009 Manuscript - Secondary Endpoint - Primary Analysis - GI - C89803 , C150705
An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Bhardwaj, S , Holland, J F ... - - Cancer Invest. - 1993 Manuscript - Primary Endpoint - Primary Analysis - Breast - C8743
Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105 Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J. Clin. Oncol. - 2006 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30105
Impact of young (Y) age on efficacy and safety in advanced colorectal cancer (aCRC): A pooled analysis examining 6,286 patients (pts) from nine first-line phase III chemotherapy (CT) trials Blanke, C. D. , Bot, B. M. , Thomas, D. M. , Bleyer, A. , Kohne, C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N9741
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials Blanke, Charles D. , Bot, Brian M. , Thomas, David M. ... - - J. Clin. Oncol - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9741
Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. Bleiberg, H. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-79-41-51 , NCCTG-83-41-51
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - A071101
Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502 Blum, K. A. , Johnson, J. L. , Jung, S.-H. , Cheson, B. D. ... - - Blood - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism Blum, K. A. , Jung, S.-H. , Johnson, J. L. , Lin, T. S. , Hsi, E. D. ... - - Ann Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50502
Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance) Blum, Kristie A. , Jung, Sin-Ho , Barak, Ian , Hsi, Eric D. ... - ASH - Blood - 2017 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904
Randomized Trial of Ofatumumab and Bendamustine versus Ofatumumab, Bendamustine and Bortezomib in previously untreated patients with highrisk follicular lymphoma: CALGB 50904 (Alliance) Blum, Kristie A. , Polley, Mei-Yin , Jung, Sin-Ho ... - - Cancer - 2019 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50904
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Leuk. Lymphoma - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50206
Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153. Blum, Kristie A , Johnson, Jeffrey L , Niedzwiecki, Donna ... - - Cancer - 2006 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Lymphoma - CALGB-9153
Challenges for conducting clinical trials evaluating maintenance chemotherapy in acute myeloid leukemia (AML): a Cancer and Leukemia Group B (CALGB) study Blum, W. , Donohue, K. , Marcucci, G. , Deangelo, D. J. , Uy, G. L. ... - ASH - Blood - 2010 Abstract - No-Endpoint Endpoint - Comprehensive Analysis - Leukemia - CALGB-10503
Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) Blum, W. , Sanford, B. , Klisovic, R. B. , Deangelo, D. J. , Uy, G. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503) Blum, William , Sanford, Ben L. , Klisovic, Rebecca ... - - Leukemia - 2017 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10503
Accelerated conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) in patients with pulmonary dysfunction: A CALGB phase I study. Bogart, J. , Watson, D. , Seagren, S. , Blackstock, W. , Wang, X. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904
Phase I Study of Accelerated Conformal Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Patients With Pulmonary Dysfunction: CALGB 39904 Bogart, Jeffrey A. , Hodgson, Lydia , Seagren, Stephen L. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-39904
Interruptions Of Once-Daily Thoracic Radiotherapy Do Not Correlate With Outcomes In Limited Stage Small Cell Lung Cancer: Analysis of CALGB Phase III Trial 9235 Bogart, Jeffrey A. , Watson, Dorothy , McClay, Edward F. ... - - Lung Cancer - 2008 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9235
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52 Bolton, J. S. , O'Connell, M. J. , Mahoney, M. R. , Farr, G. H. Jr ... - - Clin Colorectal Cancer - 2012 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-924652
Laparoscopically assisted vs open colectomy for colon cancer: a meta-analysis. Bonjer, H Jacob , Hop, Wim C J , Nelson, Heidi , Sargent, Daniel J ... - - Arch Surg - 2007 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-1515
Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance) Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N1153
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 Boughey, J. C. , Suman, V. J. , Mittendorf, E. A. , Ahrendt, G. M. ... - SSO - Annals of Surgical Oncology - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance) Boughey, Judy C. , Ballman, Karla V. , Hunt, Kelly K. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Le-Petross, Huong T. ... - - Ann. Surg. - 2016 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla V. , Symmans, William F. ... - SABCS - Cancer Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda , Byrd, David ... - ASA - - 2017 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z1071
Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071 Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance) Boughey, Judy C. , Ballman, Karla , McCall, Linda ... - SABCS - Cancer Res. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial Boughey, Judy C. , McCall, Linda M. , Ballman, Karla V. ... - - Ann. Surg. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance). Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance) Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - Ann. Surg. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - JAMA - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071
Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer; Results from CALGB 159902 Boylan, Alice M. , Wang, Xiaofei F , Ko, Richard , Watson, Patricia M ... - - J. Thorac. Cardiovasc. Surg. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-159902
LACE-Bio: validation of prognostic role of tumour lymphocytic infiltration in resectable non small cell lung cancer Brambilla, E. , Domerg, C. , Lantuejoul, S. , Kratzke, R. ... - - J Thorac Oncol - 2012 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
LACE-Bio: results of pooled analysis of prognostic and predictive values of histology and lymphocytic infiltration Brambilla, E. , Tsao, M. , Paris, E. , Lantuejoul, S. ... - - Ann. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer Brambilla, Elisabeth , Le Teuff, Gwénaël , Marguet, Sophie ... - - J. Clin. Oncol - 2016 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-9633
Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401. Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Neuro-Onc - A071401
Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Brown, Justin C , Zhang, Sui , Niedzwiecki, Donna , Saltz, Leonard B ... - - JNCI Cancer Spectr - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803
A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM) Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0177
Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance) Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W. ... - - Neurooncol Pract - 2015 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-86-72-51
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases. Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases Brown, Paul D. , Jaeckle, Kurt , Ballman, Karla V. , Farace, Elana ... - - JAMA - 2016 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177 Brown, Paul D. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0177
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial Brown, Paul D , Ballman, Karla V , Cerhan, Jane H , Anderson, S Keith ... - - Lancet Oncol. - 2017 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C
Phase II Trial of Oral Topotecan and Intravenous Carboplatin With G-CSF Support in Previously Untreated Patients With Extensive Stage Small Cell Lung Cancer Bryce, Alan H. , Mattar, Bassam , Hillman, Shauna L. , Adjei, Alex A. ... - - Am. J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-0027
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. Buckner, Jan C , O'Fallon, Judith R , Dinapoli, Robert P ... - - J. Neurooncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-94-72-52
Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study Burstein, H. J. , Barry, W. T. , Cirrincione, C. , Chew, H. K. ... - - Cancer Res. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance) Burstein, Harold J. , Cirrincione, Constance T. , Barry, William T. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40302
Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041) Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Preliminary Analysis - Breast - ACOSOG-Z1041
ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC → P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - SABCS - Cancer Res. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - - JAMA Oncol - 2019 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial Buzdar, Aman U , Suman, Vera J , Meric-Bernstam, Funda ... - - Lancet Oncol. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance) Byrd, John C. , Ruppert, Amy S. , Heerema, Nyla A. ... - - Blood Adv - 2018 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-10404
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Byrd, John C , Peterson, Bercedis L , Rai, Kanti R , Hurd, David ... - - Leuk. Lymphoma - 2009 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19901
Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) Campbell, Jeffrey I. , Yau, Christina , Krass, Polina , Moore, Dan ... - - Breast Cancer Res. Treat. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Campbell, M. E. , Mandrekar, S. J. , Hillman, S. L. , Goldberg, R. M. ... - ASCO - J. Clin. Oncol. - 2008 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - NCCTG-N0026 , NCCTG-N9741
Waterfall plots provide detailed information on magnitude of response to conventional chemotherapy in advanced colorectal cancer (ACRC) - lessons learned from N9741. Campbell, M. , Grothey, A. , Sargent, D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9741
Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib Carey, Lisa A. , Berry, Donald A. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40601
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Breast - C40601
Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (Alliance) clinical trials Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Am. J. Hematol. - 2016 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - C9621 , C9710 , CALGB-10503 , CALGB-19808
Obesity Is An Adverse Prognostic Factor For Overall and Disease-Free Survival In Adult Acute Promyelocytic Leukemia But Not In Acute Myeloid Leukemia: A Pooled Analysis From Four Alliance Prospective Studies Castillo, Jorge J. , Mulkey, Flora , Geyer, Susan ... - - Blood - 2013 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-9621 , CALGB-9710 , CALGB-10503 , CALGB-19808
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant (NEO) CRT followed by Local Excision (LE) in uT2 Rectal Cancer (RC) Chan, E. , Shi, Q. , Garcia-Aguilar, J. , Wolff, B. G. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6041
Association of Family History with Cancer Recurrence and Survival Among Patients with Stage III Colon Cancer Chan, Jennifer A. , Meyerhardt, Jeffrey A. , Niedzwiecki, Donna ... - - JAMA - 2008 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - C89803
Innovative estimation of survival using log-normal survival modelling on ACCENT database Chapman, J W , O'Callaghan, C J , Hu, N , Ding, K , Yothers, G A ... - - Br. J. Cancer - 2013 Manuscript - No-Endpoint Endpoint - Primary Analysis - GI - N0441
Comparison of innovative estimation of efficacy to standard using the ACCENT database. Chapman, J. W. , O'Callaghan, C. , Hu, N. , Ding, K. , Yothers, G. A. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
Phase 2 Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive-Stage Small Cell Lung Cancer, N0423 Chee, Cheng E. , Jett, James R. , Bernath, Albert M. ... - - Cancer - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0423
Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib versus sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk (Alliance A031203) Chen, RC , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, M ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203
Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer Chen, Wei , Ghosh, Debashis , Raghunathan, Trivellore E. ... - - Biometrics - 2009 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-9741
EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial Cheng, H , Ballman, K , Vassilakopoulou, M , Dueck, A C ... - - Br. J. Cancer - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Predictive and prognostic value of gender in early stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. Cheung, W. Y. , Shi, Q. , O'Connell, M. , Cassidy, J. , Blanke, C. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - NCCTG-N0441
The Predictive and Prognostic Value of Sex in Early-Stage Colon Cancer: A Pooled Analysis of 33,345 Patients from the ACCENT Database Cheung, Winson Y. , Shi, Qian , O’Connell, Michael , Cassidy, James ... - - Clin Colorectal Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - GI - N0441 , NCCTG-N0441
PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials Choueiri, T.K. , Flaifel, A. , Xie, W. , Braun, D. , Ficial, M. ... - ESMO - Annal Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203
Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - - J. Clin. Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - GU - A031203
CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: results from ALLIANCE A031203 Trial. Choueiri, Toni K. , Halabi, Susan , Sanford, Ben L. , Hahn, Olwen ... - ESMO - - 2016 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Progression-free survival (PFS) by independent review results from ALLIANCE A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - ESMO - Ann Oncol - 2017 Abstract - Primary Endpoint - Primary Analysis - GU - A031203
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Choueiri, Toni K. , Hessel, Colin , Halabi, Susan , Sanford, Ben ... - - Eur. J. Cancer - 2018 Manuscript - Secondary Endpoint - Primary Analysis - GU - A031203
Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance) Chua, Katherina C. , Ho, Carol , Mushiroda, Tasei , Jiang, Chen ... - ASCPT - CLINICAL PHARMACOLOGY & THERAPEUTICS - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40101 , CALGB-40502
Incidence of late recurrence in hormone receptor-positive or negative HER2-positive breast cancer receiving adjuvant trastuzumab: The combined analysis of the NCCTG (Alliance) N9831 and NSABP (NRG) B31 Trials Chumsri, Saranya , Li, Zhou , Serie, Daniel J. ... - SABCS - Cancer Res - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - NCCTG-N9831 , NSABP B-31
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31 Chumsri, Saranya , Li, Zhuo , Serie, Daniel J. ... - - J. Clin. Oncol - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831 , NSABP B-31
Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials Chumsri, Saranya , Serie, Daniel J. , Li, Zhuo ... - - Clin. Cancer Res. - 2019 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831 , NSABP B-31
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - N9831
Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer. Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - ASCO - J Clin Oncol - 2016 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52
Stereotactic Radiosurgery with or without Whole Brain Radiotherapy for Limited Brain Metastases: A Secondary Analysis of the NCCTG N0574 (Alliance) Randomized Controlled Trial Churilla, Thomas M. , Ballman, Karla V. , Brown, Paul D. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0574
Methodological Considerations in the Design and Implementation of Clinical Trials Cirrincione, Constance T. , Lavoie Smith, Ellen M. ... - - Semin Oncol Nurs - 2014 Manuscript - No-Endpoint Endpoint - Other Analysis - Onc Nursing - Pilot
Sentinel Lymph Node Biopsy Accurately Stages the Regional Lymph Nodes for T1-T2 Oral Squamous Cell Carcinomas: Results of a Prospective Multi-Institutional Trial Civantos, Francisco J. , Zitsch, Robert P. , Schuller, David E. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52 Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001 Corless, C. L. , Ballman, K. V. , Antonescu, C. , Blanke, C. D. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial Corless, Christopher L. , Ballman, Karla V. , Antonescu, Cristina R. ... - - J. Clin. Oncol - 2014 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett, Wendy R , McCall, Linda M , Petersen, Rebecca P ... - - J. Clin. Oncol. - 2006 Manuscript - Primary Endpoint - Primary Analysis - Experimental - Z0020
ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer Cote, R. , Giuliano, A. E. , Hawes, D. , Ballman, K. V. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010
Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831 Crozier, J. A. , Moreno-Aspitia, A. , Ballman, K. V. , Dueck, A. C. ... - - Cancer - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy Crozier, Jennifer A. , Advani, Pooja P. , LaPlant, Betsy ... - - Clin. Breast Cancer - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - N0436
A pooled exploratory analysis of the effect of tumor size on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC) Cuffe, S. , Ezzalfani, M. , Bourredjem, A. , Graziano, S. L. ... - Chicago MSTO - - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633
A Pooled Exploratory Analysis of the Impact of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy (ACT) in Node Negative (N0) Non-Small Cell Lung Cancer (NSCLC). Cuffe, S. , Graziano, S. , Bourredjem, A. , Pignon, J. P. ... - - J Thorac Oncol - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-9633
A Pooled Exploratory Analysis of the Effect of Tumor Size and KRAS Mutations on Survival Benefit from Adjuvant Platinum-Based Chemotherapy in Node Negative Non-Small Cell Lung Cancer Cuffe, Sinead , Bourredjem, Abderrahmane , Graziano, Stephen ... - - J Thorac Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-9633
Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657) Cureton, Elizabeth L. , Yau, Christina , Alvarado, Michael D. ... - - Ann. Surg. Oncol. - 2014 Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007
Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance) Cushman, Stephanie M. , Jiang, Chen , Hatch, Ace J. , Shterev, Ivo ... - - Clin. Cancer Res. - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-80203
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Czuczman, M S , Leonard, J P , Jung, S , Johnson, J L , Hsi, E D ... - - Ann. Oncol. - 2012 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
A phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab (R) in previously untreated follicular lymphoma (FL): Initial report of CALGB study 50402 Czuczman, M. S. , Johnson, J. L. , Jung, S. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] Czuczman, M. S. , Leonard, J. P. , Johnson, J. L. , Jung, S.-H. ... - - Blood - 2008 Abstract - Secondary Endpoint - Primary Analysis - Lymphoma - CALGB-50402
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Czuczman, Myron S , Porcu, Pierluigi , Johnson, Jeffrey ... - - Leuk. Lymphoma - 2007 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59901
p53 Protein Expression Status and Recurrence in Men Treated With Radiation Therapy and Androgen Suppression Therapy for Higher Risk Prostate Cancer: A Prospective Phase II Cancer and Leukemia Group B Study D'Amico, A. V. , Halabi, S. , Vollmer, R. , Loffredo, M. , Mcmahon, E. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2007 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682
Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study D'Amico, Anthony V. , Halabi, Susan , Tempany, Clare ... - - Int J Radiat Oncol Biol Phys - 2008 Manuscript - Secondary Endpoint - Primary Analysis - GU - CALGB-9682
p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). D'Amico, Anthony V , Halabi, Susan , Vollmer, Robin ... - - Urology - 2008 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-159807 , CALGB-9682
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103
The impact of occult micrometastases on survival following resection of stage I non-small cell lung cancer: Final analysis of CALGB 9761 D'Cunha, J. , Wang, X. , Groth, S. S. , Vollmer, R. T. ... - IASLC (WCLC) - J Thorac Oncol - 2009 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9761
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 Damon, Lloyd E. , Johnson, Jeffrey L. , Niedzwiecki, Donna ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-59909
Validation of EORTC Prognostic Factors for Adults with Low-Grade Glioma: a Report Utilizing Intergroup 86-72-511 Daniels, Thomas B. , Brown, Paul D. , Felten, Sara J. , Wu, Wenting ... - - Int J Radiat Oncol Biol Phys - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - NCCTG-86-72-51
Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial Darling, G. , Allen, M. , Decker, P. , Ballman, K. , Landreneau, R. ... - AATS - American Association for Thoracic Oncology 90th Annual Meeting, Toronto, ON, Canada - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Number of Lymph Nodes Harvested From a Mediastinal Lymphadenectomy Darling, Gail E. , Allen, Mark S. , Decker, Paul A. , Ballman, Karla ... - - Chest - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Randomized Trial of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in the Patient with N0 or N1 (Less Than Hilar) Non-Small Cell Carcinoma: Results of the ACOSOG Z0030 Trial Darling, Gail E. , Allen, Mark S. , Decker, Paul A. , Ballman, Karla ... - - J. Thorac. Cardiovasc. Surg. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC) Das, R K , Furchtgott, L , Ou, F-S , Swanson, D , Hayete, B , Harms, B ... - ESMO - Ann Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
Bayesian machine learning on CALGB/SWOG 80405 (Alliance) and PEAK data identifies heterogeneous landscape of clinical predictors of overall survival (OS) in different populations of metastatic colorectal cancer (mCRC) Das, Rahul K , Ou, Fang-Shu , Washburn, Cecilia , Nixon, Andrew B. ... - ESMO GI - Annals of Oncology - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Dawson, Nancy A , Halabi, Susan , Ou, San-San , Biggs, David D ... - - Clin Genitourin Cancer - 2008 Manuscript - Primary Endpoint - Primary Analysis - GU - CALGB-90004
Association between 3 year (yr) disease free survival (DFS) and overall survival (OS) delayed with improved survival after recurrence (REC) in patients receiving cytotoxic adjuvant therapy for colon cancer: Updated findings from the 20,800 patient (Pt) ACCENT dataset De Gramont, A. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - GI - N0441
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801 DeAngelo, Daniel J. , Yu, Daohai , Johnson, Jeffrey L. ... - - Blood - 2007 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - CALGB-19801
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor (GIST): ACOSOG Z9000 (Alliance) intergroup phase 2 trial DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Ann. Surg. - 2013 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - GI - ACOSOG-Z9000
Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST) DeMatteo, Ronald P. , Ballman, Karla V. , Antonescu, Cristina R. ... - - Lancet - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000 Dematteo, R. P. , Owzar, K. , Antonescu, C. R. , Maki, R. ... - ASCO GI - Gastrointestinal Cancers Symposium - 2008 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9000
Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 Dematteo, R. , Owzar, K. , Maki, R. , Pisters, P. , Blackstein, M. ... - ASCO - ASCO Annual Meeting - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z9001
In-dwelling catheters are superior to talc pleurodesis in the management of malignant pleural effusions Demmy, T. L. , Gu, L. , Burkhalter, J. , Toloza, E. M. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102
Hypothetical double-consent design intervention Demmy, T. L. , Kohman, L. J. ... - CTAS - - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - CALGB-30102 , CALGB-9334
Optimal Management of Malignant Pleural Effusions (Results of CALGB 30102) Demmy, Todd L. , Gu, Lin , Burkhalter, Jack E. , Toloza, Eric M. ... - - J Natl Compr Canc Netw - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30102
A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 Devine, S. M. , Owzar, K. , Blum, W. , Deangelo, D. , Stone, R. M. ... - ASH - ASH Annual Meeting Abstracts - 2012 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502 Devine, Steven M. , Owzar, Kouros , Blum, William , Mulkey, Flora ... - - J. Clin. Oncol - 2015 Manuscript - Primary Endpoint - Primary Analysis - Transplant - CALGB-100103
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) Dickler, Maura N. , Barry, William T. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40503
Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance) Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma† Dickson, M. A. , Mahoney, M. R. , Tap, W. D. , D'Angelo, S. P. ... - - Ann. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091102
Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102
Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. Dilts, D. M. , Adjei, A. A. , Mandrekar, S. J. , Buckner, J. C. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - NCCTG-N0723
Allosteric Akt inhibitor MK2206 synergizes with bendamustine in promoting the apoptosis of chronic lymphocytic leukemia cells and selectively targets B-cell receptor mediated cytokine production Ding, W. , Shanafelt, T. D. , Lesnick, C. , Sassoon, T. , Secreto, C. ... - ASH - Blood - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Leukemia - N1087
Akt Inhibitor MK2206 Selectively Targets CLL B-cell Receptor Induced Cytokines, Mobilizes Lymphocytes and Synergizes with Bendamustine to Induce CLL Apoptosis Ding, Wei , Shanafelt, Tait D. , Lesnick, Connie E. ... - - Br. J. Haematol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Leukemia - N1087
The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance) Ding, Wei , Shanafelt, Tait D. , Zent, Clive S. , Leis, Jose F. ... - - Blood - 2013 Abstract - Primary Endpoint - Primary Analysis - Leukemia - N1087
Sublobar Resection and Iodine-125 Brachytherapy for Stage 1 NSCLC, Initial Quality Assurance Review of ACOSOG Z-4032 Dipetrillo, T. A. , Heron, D. E. , Landreneau, R. J. , Logan, D. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2009 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion Dresler, Carolyn M. , Olak, Jemi , Herndon, James E. ... - - Chest - 2005 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-9334
N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM) Dronca, R. , Perez, D. , Allred, J. , Maples, W. , Creagan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0675
Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma Dronca, Roxana S. , Allred, Jacob B. , Perez, Domingo G. ... - - Am. J. Clin. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0675
CALGB 150905 (Alliance): Rituximab broadens the anti-lymphoma response by activating unlicensed NK cells Du, Juan , Lopez-Verges, Sandra , Pitcher, Brandelyn N. ... - - Cancer Immunol Res - 2014 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - CALGB-150905 , CALGB-50402 , CALGB-50701
A phase II study of sorafenib in malignant mesothelioma: results of CALGB 30307 Dubey, Sarita , Jänne, Pasi A. , Krug, Lee , Pang, Herbert ... - - J Thorac Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30307
CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM) Dudek, A. Z. , Kindler, H. L. , Otterson, G. A. , Pang, H. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief report Dudek, A. Z. , Pang, H. , Kratzke, R. A. , Otterson, G. A. ... - - J Thorac Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30601
Randomized phase 2 study of maintenance pemetrexed versus observation for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB/Alliance) 30901 Dudek, Arkadiusz Z. , Wang, Xiaofei , Gu, Lin , Stinchcombe, Thomas ... - ASCO - J Clin Oncol - 2019 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30901
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary Endpoint - Primary Analysis - GI - N1048
Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Dueck, Amylou C. , Reinholz, Monica M. , Geiger, Xochiquetzal J. ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831
Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer) Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013 Abstract - Secondary Endpoint - Primary Analysis - Breast - N1031
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. Duggan, David B , Petroni, Gina R , Johnson, Jeffrey L ... - - J. Clin. Oncol. - 2003 Manuscript - Primary Endpoint - Primary Analysis - Lymphoma - C8952
Radiofrequency ablation of stage Ia NSCLC in medically inoperable patients: Results from ACOSOG Z4033 (Alliance) an NCI funded multicenter trial Dupuy, D. E. , Fernando, H. , Hillman, S. , Ng, T. , Tan, A. D. ... - CHEST - Chest - 2013 Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033
Radiofrequency Ablation of Stage IA NSCLC in Medically Inoperable Patients: Results from the ACOSOG Z4033 (Alliance) Trial Dupuy, Damian E. , Fernando, Hiran C. , Hillman, Shauna , Ng, Thomas ... - - Cancer - 2015 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4033
A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Dy, G. K. , Mandrekar, S. J. , Nelson, G. D. , Ross, H. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0528
N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2) Dy, G. K. , Molina, J. , Qi, Y. , Ansari, R. H. , Thomas, S. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821
A Front-Line “Window of Opportunity” Phase II Study of Sorafenib in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)– A North Central Cancer Treatment Group Study N03261 Dy, Grace K. , Hillman, Shauna L. , Rowland, Kendrith M. ... - - Cancer - 2010 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0326
Long-Term Survivors of Metastatic Colorectal Cancer Treated with Systemic Chemotherapy Alone: A North Central Cancer Treatment Group Review of 3811 Patients, N0144 Dy, Grace K. , Hobday, Timothy J. , Nelson, Garth ... - - Clin Colorectal Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - GI - N0144
A Randomized Phase II Study of Gemcitabine and Carboplatin With or Without Cediranib as First-Line Therapy in Advanced Non-Small Cell Lung Cancer: North Central Cancer Treatment Group Study N0528 Dy, Grace K. , Mandrekar, Sumithra J. , Nelson, Garth D. ... - - J Thorac Oncol - 2013 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0528
NCCTG N0821 (Alliance): A phase II first-line study of pemetrexed, carboplatin and bevacizumab in elderly patients with advanced nonsquamous non-small cell lung cancer with good performance status Dy, Grace K. , Molina, Julian R. , Qi, Yingwei , Ansari, Rafat ... - - J Thorac Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0821
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741. Dy, Grace K , Krook, James E , Green, Erin M , Sargent, Daniel J ... - - J. Clin. Oncol. - 2007 Manuscript - Secondary Endpoint - Primary Analysis - GI - N9741
Prognostic and predictive impact of NPM1/FLT3-ITD genotypes as defined by 2017 European LeukemiaNet (ELN) risk categorization from randomized patients with acute myeloid leukemia (AML) treated within the International RATIFY Study (ALLIANCE 10603) Döhner, Konstanze , Thiede, Christian , Jahn, Nikolaus ... - EHA - HemaSphere - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients treated within the RATIFY/CALGB 10603 (Alliance) Study Döhner, Konstanze , Thiede, Christian , Larson, Richard A. ... - ASH - Blood - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Leukemia - CALGB-10603
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Cancer Chemother. Pharmacol. - 2015 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091103
A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401) D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Lancet Oncol. - 2018 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091401
A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401) D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401
CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer. Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - AUA - Journal of Urology - 2019 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203
CALGB 90203 (Alliance): Radical Prostatectomy with or without neoadjuvant chemohormonal therapy in men with clinically localized, high risk prostate cancer Eastham, J.A. , Heller, G. , Halabi, S. , Monk, J. P. , Beltran, H. ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Primary Endpoint - Primary Analysis - GU - CALGB-90203
Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304 Edelman, M. J. , Hodgson, L. D. , Wang, X. , Christenson, R. H. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304
Eicosanoid modulation in advanced non-small cell lung cancer (NSCLC): CALGB 30203 Edelman, M. J. , Watson, D. M. , Wang, X. , Kratzke, R. A. ... - - J. Clin. Oncol. - 2006 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203
Serum Vascular Endothelial Growth Factor and COX-2/5-LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304 Edelman, Martin J. , Hodgson, Lydia , Wang, Xiaofei ... - - J Thorac Oncol - 2011 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - CALGB-150304 , CALGB-30203
Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance) Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - MSTO - Int. J. Radiat. Oncol. Biol. Phys. - 2017 Abstract - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance) Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - - J. Clin. Oncol - 2017 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30801
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. Edelman, Martin J , Watson, Dee , Wang, Xiaofei , Morrison, Carl ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - CALGB-30203
Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial Eiger, D. , Ponde, N. F. , Agbor-Tarh, D. , Moreno-Aspitia, Alvaro ... - ESMO Breast - Annals of Oncology - 2019 Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ALTTO
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma Ellingson, Benjamin M , Abrey, Lauren E , Nelson, Sarah J ... - - Neuro-oncology - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - N0874
ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer Ellis, M. J. , Buzdar, A. U. , Unzeitig, G. W. , Esserman, L. J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10% Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012 Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy ... - - J. Clin. Oncol - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031 Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy , Lin, Li ... - - J. Clin. Oncol. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031
CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer Enzinger, P. C. , Burtness, B. , Hollis, D. R. , Niedzwiecki, D. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - GI - CALGB-80403
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers Enzinger, Peter C. , Burtness, Barbara Ann , Niedzwiecki, Donna ... - - J. Clin. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - GI - CALGB-80403 , ECOG-1206
Nut Consumption and Survival in Stage III Colon Cancer Patients: Results from CALGB 89803 (Alliance) Fadelu, Temidayo , Sui Zhang , Donna Niedzwiecki , Xing Ye ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-89803
Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance) Fadelu, Temidayo , Zhang, Sui , Niedzwiecki, Donna , Ye, Xing ... - - J. Clin. Oncol - 2018 Manuscript - Secondary Endpoint - Primary Analysis - GI - CALGB-89803
A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study Farag, S. , Owzar, K. , Hars, V. , Lazarus, H. M. , Stadtmauer, E. A. ... - ASH - Blood - 2009 Abstract - Primary Endpoint - Primary Analysis - Transplant - CALGB-100101
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Aged 60–70 Years with Acute Myeloid Leukemia in First Remission Farag, Sherif S. , Maharry, Kati , Zhang, Mei-Jie , Pérez, Waleska S. ... - - Biol. Blood Marrow Transplant. - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Leukemia - CALGB-9720 , CALGB-10201
Lymphatic Drainage Patterns in Oral Squamous Cell Carcinoma: Findings of the ACOSOG Z0360 (Alliance) Study Farmer, Roger W. , McCall, Linda , Civantos, Francisco J. ... - - Otolaryngol Head Neck Surg - 2015 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z0360
Causal modeling of CALGB 80405 (Alliance) identifies network drivers of metastatic colorectal cancer (CRC) Federico Innocenti , Heinz-Josef Lenz , Jeffrey Meyerhardt ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GI - CALGB-80405
ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203) Feldman, D , Feuilly, M , Meng, J , Lister, J , Marteau, F , Morris, MJ ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - GU - A031203
Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601
Thirty and Ninety Day Outcomes After Sublobar Resection of High-risk Patients with Non-small cell lung cancer (NSCLC); Results from a multicenter phase III study Fernando, H. C. , Landreneau, R. J. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 91st Annual Meeting - 2011 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea: Preliminary Results from ACOSOG Z4032 Trial Fernando, H. C. , Landreneau, R. , Mandraker, S. , Hillman, S. ... - AATS - American Association of Thoracic Surgery 90th Annual Meeting - 2010 Abstract - Primary Endpoint - Preliminary Analysis - Respiratory - ACOSOG-Z4032
Impact of brachytherapy on local recurrence after sublobar resection: Results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small cell lung cancer (NSCLC) Fernando, H. , Landreneau, R. , Mandrekar, S. , Nichols, F. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer Fernando, Hiran C. , Landreneau, Rodney J. , Mandrekar, Sumithra J. ... - - J. Clin. Oncol - 2014 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: A randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non–small cell lung cancer Fernando, Hiran C. ... - - J. Thorac. Cardiovasc. Surg. - 2012 Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Respiratory - ACOSOG-Z4099
The Impact of Adjuvant Brachytherapy with Sublobar Resection on Pulmonary Function and Dyspnea in High-risk Operable Patients; Preliminary results from the ACOSOG Z4032 Trial Fernando, Hiran C , Landreneau, Rodney J , Mandrekar, Sumithra J ... - - J Thorac Cardiovasc Surg - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z4032
Dose intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710 Feusner, J. , Gregory, J. , Moser, B. K. , Hars, V. , Powell, B. L. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary Endpoint - Primary Analysis - Leukemia - C9710
Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030) Fibla, J. J. , Cassivi, S. D. , Decker, P. A. , Allen, M. S. ... - - J. Clin. Oncol. - 2010 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set Fibla, Juan J. , Cassivi, Stephen D. , Brunelli, Alessandro ... - - Lung Cancer - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030) Fibla, Juan J. , Cassivi, Stephen D. , Decker, Paul A. ... - - Eur J Cardiothorac Surg - 2013 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Respiratory - ACOSOG-Z0030
Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial Fleming, Gini F , Francis, Prudence A , Láng, István ... - SABCS - Ann. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Five year results from the COST trial testing laparoscopic versus open colectomy for colon cancer Fleshman, J. , Sargent, D. , Green, E. , Anvari, M. , Stryker, S. ... - - EJC Supplement - 2007 Abstract - Primary Endpoint - Primary Analysis - GI - INT-0146
Disease Free Survival and Local Recurrence for Laparoscopic Resection Compared to Open Resection of Stage II-III Rectal Cancer: Follow up Results of the ACOSOG Z6051 Randomized Controlled Trial Fleshman, J , Branda, ME , Sargent, DJ , Boller, AM , George, VV ... - - Ann. Surg. - 2019 Manuscript - Secondary Endpoint - Primary Analysis - GI - ACOSOG-Z6051
Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes Fleshman, James , Branda, Megan , Sargent, Daniel J. ... - - JAMA - 2015 Manuscript - Primary Endpoint - Primary Analysis - GI - ACOSOG-Z6051
Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial. Fleshman, James , Sargent, Daniel J , Green, Erin , Anvari, Mehran ... - - Ann. Surg. - 2007 Manuscript - Primary Endpoint - Primary Analysis - GI - NCCTG-1515
Age, Gender, Performance Status and Stage Outperformed Stage alone in Predicting Overall Survival (OS) in Patients with Small Cell Lung Cancer: A Pooled Analysis of 1623 patients from the North Central Cancer Treatment Group. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation. Foster, N. R. , Mandrekar, S. J. , Schild, S. E. , Nelson, G. D. ... - - J. Clin. Oncol. - 2008 Abstract - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Foster, N. R. , Qi, Y. , Krook, J. E. , Kugler, J. W. , Kuross, S. A. ... - - J. Clin. Oncol. - 2009 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - N0424
Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Foster, N. R. , Qi, Y. , Shi, Q. , Krook, J. E. , Kugler, J. W. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Respiratory - NCCTG-N0424
Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis Foster, N. R. , Renfro, L. A. , Schild, S. E. , Redman, M. W. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - Comprehensive , CALGB-9033 , CALGB-9732 , CALGB-30103 , NCCTG-862051 , NCCTG-892051 , NCCTG-932053 , ECOG-1500 , ECOG-7593 , JCOG-9511 , NCIC-BR4 , NCIC-BR8 , SWOG-S0124
Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. Foster, N. R. , Sinicrope, F. , Yothers, G. , Allegra, C. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - GI - N994C
Prognostic factors differ by tumor stage for Small Cell Lung Cancer: A Pooled Analysis of North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Mandrekar, Sumithra J. , Schild, Steven E. ... - - Cancer - 2009 Manuscript - Secondary Endpoint - Primary Analysis - Respiratory - N0424
Tumor Response and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Findings Based on North Central Cancer Treatment Group (NCCTG) Trials Foster, Nathan R. , Qi, Yingwei , Shi, Qian , Krook, James E. ... - - Cancer - 2011 Manuscript - Primary Endpoint - Primary Analysis - Respiratory - N0424
Multi-Trial Evaluation of Progression-Free Survival (PFS) as a Surrogate Endpoint for Overall Survival (OS) in First-Line Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Foster, Nathan R. , Renfro, Lindsay A. , Schild, Steven E. ... - - J Thorac Oncol - 2015 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Respiratory - CALGB-30103 , N0424 , NCCTG-932053
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Francis, P. A. , Pagani, O. , Fleming, G. F. , Walley, B. A. ... - - N. Engl. J. Med. - 2018 Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT) , IBCSG-25-02 (TEXT) , S0002
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer Francis, Prudence A. , Regan, Meredith M. , Fleming, Gini F. ... - - N. Engl. J. Med. - 2015 Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Long-Term Follow-Up of TEXT and SOFT Trials of Adjuvant Endocrine Therapies for Premenopausal Women with HR+ Early Breast Cancer Francis, Prue , Fleming, Gini , Regan, Meredith , Pagani, Olivia ... - SABCS - Cancer Res - 2017 Abstract - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of NCCTGs phase III trials N9741 and N9841. Franko, J. , Shi, Q. , Goldman, C. D. , Pockaj, B. A. , Nelson, G. D. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9841 , N9741
Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841 Franko, Jan , Shi, Qian , Goldman, Charles D. , Pockaj, Barbara A. ... - - J Clin Oncol - 2012 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - GI - N9841 , N9741
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in stage II and III colon cancers.
